Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE�) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis

NCT00336492 is registered in ClinicalTrials.gov with Centocor, Inc. as lead sponsor.

NCT NCT00336492
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00336492 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE�) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis
Lead sponsor
Centocor, Inc.
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2006
Completion date
April 30, 2010
Enrollment
60 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis